Source:http://linkedlifedata.com/resource/pubmed/id/16787328
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
5
|
pubmed:dateCreated |
2006-6-21
|
pubmed:abstractText |
The syntheses of (R)- and (S)-norcarnitine ethyl esters are described starting with an optimized, chiral chemical reduction of ethyl 4-chloroacetoacetate followed by azide substitution, reduction, and dimethylation. The reaction of (R)- and (S)-norcarnitine ethyl esters with 1-bromoheptadecan-2-one gives (+)- and (-)-6-[(methoxycarbonyl)methyl]-2-pentadecyl-4,4-dimethylmorpholinium bromide, respectively, which hydrolyzes to (+)- and (-)-6-(carboxylatomethyl)-2-pentadecyl-4,4-dimethylmorpholinium (hemipalmitoylcarnitinium, (+)- and (-)-HPC), respectively, upon treatment with a hydroxide resin. (+)- and (-)-HPC are reversible active-site directed inhibitors of hepatic mitochondrial CPTs. Both stereoisomers inhibit CPT I and CPT II in control and streptozotocin diabetic rat to the same extent (Imax=100%). Using intact mitochondria (CPT I), I50values for (-)-HPC and (+)-HPC were 15.5 microM and 47.5 microM, respectively. The I50 values for CPT II were 6.7 microM and 38.5 microM for (-)-HPC and (+)-HPC, respectively. The mode of inhibition was uncompetitive for CPT I with respect to acyl-CoA. The apparent K(i) for (-)-HPC is about 5 microM. These data suggest that (-)-HPC may be useful for further evaluation as an antidiabetic agent.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Sep
|
pubmed:issn |
1573-4064
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
1
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
445-53
|
pubmed:dateRevised |
2008-2-26
|
pubmed:meshHeading |
pubmed-meshheading:16787328-Animals,
pubmed-meshheading:16787328-Binding Sites,
pubmed-meshheading:16787328-Carnitine O-Palmitoyltransferase,
pubmed-meshheading:16787328-Diabetes Mellitus, Experimental,
pubmed-meshheading:16787328-Disease Models, Animal,
pubmed-meshheading:16787328-Intracellular Membranes,
pubmed-meshheading:16787328-Male,
pubmed-meshheading:16787328-Mitochondria, Liver,
pubmed-meshheading:16787328-Molecular Conformation,
pubmed-meshheading:16787328-Palmitoylcarnitine,
pubmed-meshheading:16787328-Rats,
pubmed-meshheading:16787328-Rats, Sprague-Dawley,
pubmed-meshheading:16787328-Stereoisomerism,
pubmed-meshheading:16787328-Structure-Activity Relationship
|
pubmed:year |
2005
|
pubmed:articleTitle |
Comparison of (+)- and (-)-hemipalmitoylcarnitinium as inhibitors of hepatic mitochondrial carnitine palmitoyltransferases in diabetic rats.
|
pubmed:affiliation |
Department of Chemistry (MC 0212) Virginia Tech, Blacksburg, VA, USA.
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, U.S. Gov't, Non-P.H.S.,
Research Support, Non-U.S. Gov't
|